Table 7.

Point estimates and 95% confidence intervals for the comparison of dose-normalized upadacitinib parameters between healthy Japanese or Chinese subjects and healthy Western subjects

Regimens (test vs. reference)	Pharmacokinetic parameter	Point estimate	95% CI
Heathy Japanese subjects (test) vs. healthy Western subjects (reference) (immediate-release formulation)	Dose-normalized Cmax	1.083	0.935–1.255
	Dose-normalized AUC12	1.176	1.056–1.310
Heathy Chinese subjects (test) vs. healthy Western subjects (reference) (immediate-release formulation)	Dose-normalized Cmax	1.076	0.838–1.382
	Dose-normalized AUC12	1.029	0.856–1.235

AUC₁₂ area under the plasma concentration–time curve from time zero to 12 h, CI confidence interval, C_max maximum concentration